Literature DB >> 25847300

A tale of two macrophages: to Shb or not to Shb.

J L Arbiser1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25847300      PMCID： PMC4430344          DOI： 10.1111/apha.12504

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN： 1748-1708            Impact factor:   6.311


× No keyword cloud information.
  6 in total

1.  Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer.

Authors:  Lunxu Liu; Dongxia Ge; Lin Ma; Jiandong Mei; Sen Liu; Qiuyang Zhang; Fuqiang Ren; Hu Liao; Qiang Pu; Tao Wang; Zongbing You
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

2.  Shb deficiency in endothelium but not in leucocytes is responsible for impaired vascular performance during hindlimb ischaemia.

Authors:  M Nikpour; K Gustafsson; E Vågesjö; C Seignez; A Giraud; M Phillipson; M Welsh
Journal:  Acta Physiol (Oxf)       Date:  2015-01-17       Impact factor: 6.311

3.  Expression of the human immunodeficiency virus type-1 coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ hematopoietic progenitor cells.

Authors:  M Deichmann; R Kronenwett; R Haas
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

Review 4.  The macrophage in HIV-1 infection: from activation to deactivation?

Authors:  Georges Herbein; Audrey Varin
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

5.  Shb deficient mice display an augmented TH2 response in peripheral CD4+ T cells.

Authors:  Karin Gustafsson; Gabriela Calounova; Fredrik Hjelm; Vitezslav Kriz; Birgitta Heyman; Kjell-Olov Grönvik; Gustavo Mostoslavsky; Michael Welsh
Journal:  BMC Immunol       Date:  2011-01-11       Impact factor: 3.615

6.  Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation.

Authors:  Mirjam Stahl; Jonas Schupp; Benedikt Jäger; Michael Schmid; Gernot Zissel; Joachim Müller-Quernheim; Antje Prasse
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.